Drugs / Alcestobart
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT05609370 | Jan 2023 → May 2025 overdue | colorectal cancer | BeiGene | Active not recruiting | Missed primary |
| Phase 1/2 | NCT03744468 | Nov 2018 → Feb 2025 | head and neck squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05577702 | Mar 2023 → Dec 2024 | non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alcestobart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03744468 ↗ |
| Action | Inhibit | “alcestobart (Anti-LAG-3)” NCT03744468 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068199 ↗ |
| Route | Intravenous | “alcestobart 300 mg IV infusion on day 1 of each cycle” NCT03744468 ↗ |